Research And Development Arrangement, Contract To Perform For Others, Commercial Milestones, Maximum Amount

No definition available.

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialMilestonesMaximumAmount
Namespace Prefix:	mrna_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research And Development Arrangement, Contract To Perform For Others, Development And Regulatory Milestones, Maximum Amount

+ References

No definition available.

+ Details

Name:	mrna_ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentAndRegulatoryMilestonesMaximumAmount
Namespace Prefix:	mrna_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_SublicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_TherapeuticAndProphylacticProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=mrna_DiagnosticProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Licenses to Patented Technology (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018	Jun. 26, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Commercial milestone payments			$ 24.0
Consideration paid	$ 6.9
Sublicense agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Expenses associated with license agreements		$ 22.0
Therapeutic and prophylactic products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and regulatory milestone payments			1.5
Diagnostic products
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and regulatory milestone payments			$ 0.5